A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases.
Lucie Isoline PisellaSara FernandesGuilhem SoléTanya StojkovicCéline TardJean-Baptiste ChansonFrançoise BouhourEmmanuelle Salort-CampanaGuillemette BeaudonnetLouise DebergéFanny DuvalAude-Marie GrapperonMarion MasingueAleksandra Nadaj-PaklezaYann PéréonFrédérique AudicAnthony BehinDiane FriedmanArmelle MagotJean-Baptiste NourySarah SouvannanorathKarim WahbiJean-Christophe AntoineKévin BigautJean-Philippe CamdessanchéPascal CintasRabab DebsCaroline Espil-TarisLaurent KremerThierry KuntzerPascal LaforêtVincent LaugelMartial MallaretMaud MichaudSylvain NolletJuliette SvahnSavine VicartRocio Nur Villar-QuilesIsabelle DesguerreDavid AdamsSandrine Segovia-KuenyGéraldine MerretElhadi HammoudaAnnamaria MolonShahram AttarianPublished in: Orphanet journal of rare diseases (2021)
During this period, a small percentage of French NMD patients was affected by COVID-19 compared to the general French population and COVID-19 had a limited short-term effect on them. Diabetes, hypertension and a severe degree of NMD were identified as risk factors of unfavorable outcome following COVID-19. Conversely, in our cohort of patients with acquired NMD, corticosteroids or other immunosuppressants did not appear to be risk factors for more severe COVID-19.